Regeneration difficulties in patients with FQAD can limit the use of iPSc-based cell therapy

Etiopathogenesis of fluoroquinolone-associated disability (FQAD) syndrome is not fully understood, yet research could progress by utilizing induced pluripotent stem cells (iPSc) from people with this syndrome. Similarly, iPSc, or rather their derivatives, could be used in their therapy, not only for...

Descripción completa

Detalles Bibliográficos
Autores principales: Grot, Dagmara, Wasiak, Katarzyna, Tyszkowski, Jerzy, Stoczynska-Fidelus, Ewelina, Ochedalski, Tomasz P., Rieske, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123688/
https://www.ncbi.nlm.nih.gov/pubmed/35598007
http://dx.doi.org/10.1186/s13287-022-02886-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123688/
https://www.ncbi.nlm.nih.gov/pubmed/35598007
http://dx.doi.org/10.1186/s13287-022-02886-0

Ejemplares similares